• Biton V, Levisohn P, Hoyler S, Vuong A, Hammer AE. (2003) Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol 18:133139.
  • Biton V. (2006) Weight change and antiepileptic drugs: health issues and criteria for appropriate selection of an antiepileptic agent. Neurologist 12:163167.
  • Chandran M, Phillips SA, Ciaraldi T, Henry RR. (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26:24422450.
  • Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT, Lai MM, Lin CC. (2007) The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 56:12161220.
  • Commission on Classification and Terminology of the International League Against Epilepsy. (1989) Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389399.
  • Davis R, Peters DH, McTavish D. (1994) Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47:332372.
  • Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. (1987) Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:5459.
  • Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426430.
  • Greco R, Latini G, Chiarelli F, Iannetti P, Verrotti A. (2005) Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 65:18081809.
  • Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O, Kapiotis S, Wolzt M. (2006) The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 43:548549.
  • Korner A, Kratzsch J, Gausche R, Schaab M, Erbs S, Kiess W. (2007) New predictors of the metabolic syndrome in children—role of adipocytokines. Pediatr Res 61:640645.
  • Kromeyer-Hauschild K, Wabitsch M, Kunze D, Geller F, Gneiß H, Hesse V, Von Hippel A, Jaeger U, Johnsen D, Korte W, Menner K, Mueller G, Mueller J, Niemann-Pilatus A, Remer T, Schaefer F, Wittchen H, Zabransky S, Zellner K, Ziegler A, Hebebrand J. (2001) Perzentilen für den body-mass-index für das kindes- und jugendalter unter heranziehung verschiedener deutscher stichproben. Monatsschrift Kinderheilkunde 149:807818.
  • Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I, Bauer G, Lechleitner M. (2004) Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 55:729732.
  • Matsuzawa Y. (2006) The metabolic syndrome and adipocytokines. FEBS Lett 580:29172921.
  • Pecoraro P, Guida B, Caroli M, Trio R, Falconi C, Principato S, Pietrobelli A. (2003) Body mass index and skinfold thickness versus bioimpedance analysis: fat mass prediction in children. Acta Diabetol 40(Suppl 1):S278S281.
  • Pylvanen V, Pakarinen A, Knip M, Isojarvi J. (2006) Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 8:643648.
  • Stefan N, Bunt JC, Salbe AD, Funahashi T, Matsuzawa Y, Tataranni PA. (2002) Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab 87:46524656.
  • Tilg H, Moschen AR. (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772783.
  • Yamashita S, Nakamura T, Shimomura I, Nishida M, Yoshida S, Kotani K, Kameda-Takemuara K, Tokunaga K, Matsuzawa Y. (1996) Insulin resistance and body fat distribution. Diabetes Care 19:287291.